Citation: | ZHANG Yilun, ZHAO Xinyi, DONG Shubo, DONG Chao, SHEN Wenbin, DONG Haijuan. Isolation and identification of unknown impurities of alogliptin benzoate[J]. Journal of China Pharmaceutical University, 2020, 51(4): 488-493. DOI: 10.11665/j.issn.1000-5048.20200415 |
[1] |
Feng J,Zhang Z,Wallace M B,et al. Discovery of alogliptin: a potent,selective,bioavailabe and efficacious inhibitor of dipeptidyl peptidase IV[J]. J Med Chem,2007,50(10):2297-2300.
|
[2] |
Zhang SF. Approval for marketing of the new diabetes drug,NESINA[J]. Chin Lic Pharm(中国执业药师),2010,12(6):54.
|
[3] |
Scott L J.Alogliptin: a review of its use in the management of type 2 diabetes mellitus[J]. Drugs, 2010, 70(18):2051-2072.
|
[4] |
Li RF,Ouyang XY,lv F,et al.Analysis for patents of anti-diabetic dipeptidyl peptidase inhibitors[J]. Chin New Drugs J(中国新药杂志),2015,24(1):8-17.
|
[5] |
Shen D,Wang ZJ,Xu C,et al.Synthesis of alogliptin benzoate and its preliminary quality control[J]. Central South Pharm(中南药学),2016,14(9):813-816.
|
[6] |
Lu YT,Yang DY ,Li ZY,et al. Isolation and characterization of related substances in alogliptin benzoate by LC-QTOF mass spectrometric techniques[J]. J Pharm Biomed Anal,2016,128:253-263.
|
[7] |
Zhang K,Ma PQ,Jing WN,et al. A developed HPLC method for the determination of alogliptin benzoate and its potential impurities in bulk drug and tablets[J]. Asian J Pharm Sci,2015,10:152-158.
|
[8] |
Zhou XY,Rong R,ZhaoYL,et al. Determination of related substances in alogliptinbenzoate by HPLC[J].J Shenyang Pharm Univ(沈阳药科大学学报),2016,33(6):444-449.
|
[9] |
Sun ZY,Qiao SQ,Luo ZL,Determination of related substances in alogliptin benzoate raw materials by HPLC [J].J China Pharm(中国药房),2014,25(33):3141-3143.
|
[10] |
Shao J,Gao S,Li XX,et al.Determination of alogliptin benzoate and its related substances [J]. J Shenyang Pharm Univ(沈阳药科大学学报),2015,32(10):780-785.
|
[11] |
Liu ZW,Wu LH,Wang EJ.Synthesis of alogliptin benzoate [J]. Strait Pharm(海峡药学),2011,23(9):214-215.
|